A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

NCT07728383 · Recruiting

Last updated 2026-08-27

This study tests a dissolvable tablet form of semaglutide placed under the tongue to see if it helps reduce body weight in adults who are overweight or have obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 40 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2026-06 · est. completion 2027-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07728383 ↗

Description as written by the study sponsor.

This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.

Treatments tested

Semaglutide 6 mg liquid emulsion formulation Drug

Semaglutide 6 mg liquid emulsion formulation daily
Wegovy® (semaglutide) Tablet also known as Wegovy® (semaglutide) Tablet 25 mg Drug

Wegovy® (semaglutide) Tablet 25 mg daily
Placebo liquid emulsion formulation Drug

Placebo liquid emulsion formulation daily

Main thing measured	Percent body weight change from baseline
Sponsor	Gila Therapeutics, Inc.
Conditions studied	Obesity & Overweight
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07728383 ↗